Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 2:13:752065.
doi: 10.3389/fimmu.2022.752065. eCollection 2022.

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development

Pottayil G Sasikumar  1 , Murali Ramachandra  1
Affiliations
Review

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development

Pottayil G Sasikumar et al. Front Immunol. .

Abstract

Pioneering success of antibodies targeting immune checkpoints such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has changed the outlook of cancer therapy. Although these antibodies show impressive durable clinical activity, low response rates and immune-related adverse events are becoming increasingly evident in antibody-based approaches. For further strides in cancer immunotherapy, novel treatment strategies including combination therapies and alternate therapeutic modalities are highly warranted. Towards this discovery and development of small molecule, checkpoint inhibitors are actively being pursued, and the efforts have culminated in the ongoing clinical testing of orally bioavailable checkpoint inhibitors. This review focuses on the small molecule agents targeting PD-1 checkpoint pathway for cancer immunotherapy and highlights various chemotypes/scaffolds and their characterization including binding and functionality along with reported mechanism of action. The learnings from the ongoing small molecule clinical trials and crucial points to be considered for their clinical development are also discussed.

Keywords: PD-L1 inhibitors; cancer immunotherapy; mechanism of action (MOA); small molecule PD-1/PD-L1 inhibitors; small molecule immunomodulators.

PubMed Disclaimer

Conflict of interest statement

Authors are present or previous employees of Aurigene Discovery Technologies Limited. PS and MR are inventors on several patent applications related to immune checkpoint inhibitors described in this manuscript. MR is the CEO of Aurigene Discovery Technologies Limited, a company that is co-developing CA-170 for cancer therapy.

Figures

Figure 1
Figure 1
Compounds based on the biphenyl scaffold, originally identified by a conventional approach of screening compounds in an assay for prevention of the PD-1, PD-L1 interaction.
Figure 2
Figure 2
Representative structures of first-generation biphenyl derivatives and C2 symmetric compounds targeting PD-L1.
Figure 3
Figure 3
Representative structures of modified biphenyl analogues without C2 symmetry but with improved druggability.
Figure 4
Figure 4
Amino-acid-inspired small molecules mimicking the receptor–ligand interface identified in a functional assay.
Figure 5
Figure 5
Representative structures of amino-acid-inspired interface mimics targeting PD-L1.
Figure 6
Figure 6
Two distinct mechanisms leading to functional antagonism with reported small molecule PD-L1 inhibitors.
See this image and copyright information in PMC

References

    1. Ledford H, Else H, Warren M. Cancer Immunologists Scoop Medicine Nobel Prize. Nature (2018) 562(7725):20–1. doi: 10.1038/d41586-018-06751-0 - DOI - PubMed
    1. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors Per NCCN Guidelines With the Level of Evidence. Cancers (2020) 12(3):735. doi: 10.3390/cancers12030738 - DOI - PMC - PubMed
    1. Pardoll DM. The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nat Rev Cancer (2012) 12(4):252–64. doi: 10.1038/nrc3239 - DOI - PMC - PubMed
    1. Ghosh A, Barba P, Perales M-A. Checkpoint Inhibitors in AML: Are We There Yet? Br J Haematol (2020) 188(1):159–675. doi: 10.1111/bjh.16358 - DOI - PMC - PubMed
    1. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the Anti-PD-1 and Anti-PD-L1 Immune Checkpoint Antibodies. Ann Oncol (2015) 26(12):2375–91. doi: 10.1093/annonc/mdv383 - DOI - PMC - PubMed